The invention of personalized medicine, between technological upheavals and utopia;L'invention de la médecine personnalisée

Medecine/Sciences

Volumn 31, Issue 8-9, 2015, Pages 797-803

  Billaud, Marc ^a   Guchet, Xavier ^b  

^a UNIV GRENOBLE ALPES   (France)

^b UNIVERSITÉ PARIS 1 PANTHÉON SORBONNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NOMENCLATURE; PERSONALIZED MEDICINE; PHILOSOPHY;

PRECISION MEDICINE; TERMINOLOGY AS TOPIC; UTOPIAS;

EID: 84941200893     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20153108020     Document Type: Review

References (42)

1. Cullis P. The personalized medicine revolution. How diagnosing and treating disease are about to change forever. Vancouver: Greystone Books, 2015.
2. Guchet X. Les promesses de la médecine personnalisée. In: Audétat M, Barazzetti G, Dorthe G, Joseph C, et al., eds. Sciences et technologies émergentes: pourquoi tant de promesses ? Paris: Hermann, 2015. (sous presse).
3. Marino P. Tests diagnostiques et thérapies ciblées en cancérologie. Enjeux économiques. Med Sci (Paris) 2012; 28 (hors série n° 1): 19-22.
4. Paci A. (sous la direction de). Médecine personnalisée et cancer. Organiser et financer l'accès à l'innovation. Villejuif: Presses de l'Institut Gustave Roussy, 2013.
5. Seror V. Perspective économique sur les traitements ciblés. Med Sci (Paris) 2014; 30 (hors série n° 2): 32-35.
6. Fleck LM. Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices. New Biotechnol 2012; 29: 757-768.
7. Feldman EA. The genetic information nondiscrimination act (GINA): public policy and medical practice in the age of personalized medicine. J Gen Intern Med 2011; 27: 743-746.
8. Weigman K. Racial medicine: here to stay? EMBO Rep 2006; 7: 246-249.
9. Kahn J. Race in a bottle: the story of BiDil and racialized medicine in a post-genomic age. New York: Columbia University Press, 2013.
10. Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu Rev Hum Genet 2011; 12: 217-244.
11. De Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2013; 467: 543-549.
12. Baker M. Big biology: the ome's puzzle. Nature 2013; 494: 416-419.
13. National research council. Toward precision medicine. Building a knowledge. Network for biomedical research and a new taxonomy of disease. Washington: National Academies Press, 2011.
14. Accenture. The pursuit of high performance through research and development. Understanding pharmaceutical research and development cost drivers. Accenture, 2007. Available at: http://www.accenture.com/Microsites/rdtransformation/Documents/PDFs/Accenture-In-Pursuit-of-High-Performance.pdf.
15. Langreth R, Waldholz M. New era of personalized medicine. Targeting drugs for each unique genetic profile. Oncologist 1999; 4: 426-427.
16. Morgan M. News paradigms in industry: the single nucleotide polymorphism consortium. In: Esanu JM, Uhlir PF, eds. The role of scientific and technical data and information in the public domain. Proceedings of a Symposium,. chapter 28. Washington: National Academy of Sciences, 2003.
17. Rajan KS Biocapital. The construction of postgenomic life. Duham and London: Duke University Press, 2006.
18. Food and Drugs Administration. Paving the way for personalized medicine: FDA's role in a new era of medical product development. FDA, 2013. Available at: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf.
19. Ng PC, Murray SS, Levy S, Venter JC An agenda for personalized medicine. Nature 2009; 461: 724-726.
20. NIH. Precision medicine initiative. Available at: http://www.nih.gov/precisionmedicine/
21. Topol EJ. Individualized medicine from prewomb to the tomb. Cell 2014; 157: 241-253.
22. Gaudillière JP. Inventer la biomédicine. La France, l'Amérique et la production des savoirs du vivant (1945-1965). Paris: La Découverte, 2002.
23. Mamo L, Clarke AE, Fosket JR, et al. (eds). Biomedicalization. Technoscience, health, and illness in the US. Durham: Duke University Press, 2010: 512 p.
24. Cambrosio A, Keating P. Qu'est-ce que la biomédecine ? Repères socio-historiques. Med Sci (Paris) 2013; 12: 1280-1287.
25. Foucault M. Naissance de la clinique. Une archéologie du regard médical. Paris: PUF, 1963.
26. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148: 1293-1307.
27. Nelson N, Keating P, Cambrosio A. On being actionable: clinical sequencing and the emerging contours of a regime of genomic in medicine in oncology. New Genet Soc 2013; 32: 405-428.
28. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science 2013; 339: 1546-1558.
29. Arnedos M, Viehl P, Soria JC, André F. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol 2014; 232: 274-282.
30. Callon M. Les incertitudes scientifiques et techniques constituent-elles une source possible de renouvellement de la vie démocratique ? Papiers de Recherche du CSI. Paris: Centre de Sociologie de l'Innovation, Mines ParisTech, 2012.
31. Majewski IJ, Bernards R. Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med 2011; 17: 304-312.
32. Guchet X. La médecine personnalisée. Une approche philosophique. Paris: Hermann, 2015. (sous presse).
33. Tursz T, André F, Lazar V, et al. Implications of personalized medicine-perspective from a cancer center. Nat Rev Clin Oncol 2011; 8: 177-183.
34. André F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014; 15: 267-274.
35. Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 2015; 33: 975-977.
36. Bateman S. Médecine personnalisée. Un concept flou, des pratiques diversifiées. Med Sci (Paris) 2014; 2: 8-13.
37. Institute for Systems Biology. 100K Wellness Project. Available at: http://research.systemsbiology.net/100k/
38. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011; 8: 184-187.
39. Hood L, Flores MA. Personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. New Biotechnol 2012; 29: 613-622.
40. Pinell P. Naissance d'un fléau: histoire de la lutte contre le cancer en France (1890-1940). Paris: Métailié, 1992.
41. Sfez L. La santé parfaite. Critique d'une nouvelle utopie. Paris: Seuil, 1995.
42. Rose N. Personalized medicine: promises, problems and perils of a new paradigm for healthcare. Procedia Soc Behav Sci 2013; 77: 341-352.